Efficacy and Safety of Celecoxib/Acetaminophen Versus Celecoxib for Diagnosed Osteoarthritis in Acute Exacerbation
NCT ID: NCT06863636
Last Updated: 2025-04-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
231 participants
INTERVENTIONAL
2024-09-09
2025-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (United States)
NCT00620867
Study Of "Continuous Use" Of Celecoxib Vs. "Usual or Intermittent Use"
NCT00139776
Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (Europe)
NCT00630929
Efficacy and Safety of Celecoxib Versus Placebo in the Treatment of Patients With Osteoarthritis of the Knee Who Were Unresponsive to Naproxen and Ibuprofen
NCT00640627
Celebrex Total Knee Arthroplasty Study
NCT00359151
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will:
Be randomized into one of three intervention groups (A, B, or C).
Attend five scheduled clinic visits (Day 0, and Weeks 1, 2, 4, and 6 of follow-up).
Be permitted to take 500 mg of naproxen as rescue medication, if needed, with prior authorization from the principal investigator.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Celecoxib+Acetaminophen
Administered orally, 1 tablet a day during 6 weeks
Celecoxib + Acetaminohen
One tablet of 200 mg / 200 mg a day
Celecoxib + Acetaminophen
Administered orally, 1 tablet a day during 6 weeks
Celecoxi + Acetaminophen
One tablet of 200 mg / 500 mg a day
Celecoxib
Administered orally, 1 capsule a day during 6 weeks
Celecoxib
One capsule of 200 mg a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Celecoxib + Acetaminohen
One tablet of 200 mg / 200 mg a day
Celecoxi + Acetaminophen
One tablet of 200 mg / 500 mg a day
Celecoxib
One capsule of 200 mg a day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Prior diagnosis of knee or hip osteoarthritis based on clinical criteria (according to the American College of Rheumatology (ACR) criteria described in Annex 5).
* Pain in the affected joint with exacerbation lasting no more than 3 weeks.
* Patient reports moderate to severe pain intensity (VAS ≥ 40 mm).
* For women of childbearing potential (a woman is considered fertile after menarche and until postmenopause unless permanently sterile), they must agree to use at least ONE of the following contraceptive methods during the study:
Barrier methods: diaphragm, cervical cap, male condom, female condom, spermicide foam, sponge, or film.
Hormonal methods: combined oral contraceptives, injectable contraceptives, subdermal implant, contraceptive patch.
Intrauterine device (IUD): copper or silver IUD, Levonorgestrel intrauterine system (IUS), and/or combinations of the above as deemed acceptable by the physician.
Women are considered not of childbearing potential if they meet at least ONE of the following criteria:
Postmenopausal. Premenopausal woman with at least ONE of the following: hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.
Male subjects must agree to use a male condom as a contraceptive method during the study.
* At the discretion of the Principal Investigator (PI) or treating physician, the subject has an indication for treatment with the investigational product and may derive clinical benefit from it.
Exclusion Criteria
* Participation in another clinical study involving an investigational treatment or participation in one within the last two weeks prior to the study start.
* Potential study bias due to employment or relationship with the research center, sponsor, or being part of a vulnerable population.
* Medical conditions affecting prognosis that prevent outpatient management, to be evaluated by the Principal Investigator for subject inclusion relevance.
* History of advanced, severe, progressive, or unstable disease of any kind that may interfere with efficacy and safety assessments or pose a special risk to the patient.
* Medical contraindication to the investigational product.
* History of allergic reaction to NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), Acetaminophen, or known hypersensitivity to any formulation components.
* Significant gastrointestinal disorders, such as gastric ulcers, Crohn's disease, ulcerative colitis, or gastrointestinal bleeding.
* Prior opioid treatment within the last five days, as reported in the medical history.
* History of treatment failure with COX-2 selective inhibitors, as documented in the medical history.
* History of chronic somatic pain unrelated to knee or hip osteoarthritis (e.g., fibromyalgia, metastatic disease, or Paget's disease).
* History of alcohol or drug abuse within the past year.
* Current treatment with NSAIDs, including COX-2 inhibitors, within the last 72 hours before signing informed consent (except for aspirin used for cardioprotective purposes).
* History of arthroscopy, viscosupplementation, or intra-articular steroid use in the last three months.
* Previous surgery on the affected joint within the last six months.
* Major trauma in the affected joint within the last three weeks.
* History of chronic liver failure (Child-Pugh A, B, or C).
* History of acute or severe renal failure (glomerular filtration rate \<30 ml/min/1.73 m²), as reported in the medical history.
* Significant coagulation disorders (e.g., Von Willebrand disease, hemophilia, vitamin K deficiency) or current use of anticoagulants.
Oncologic patients (except basal cell carcinoma) or those with severe illnesses that, according to the investigator, have a poor prognosis or a life expectancy of less than one year, including severe mental illness.
* Patients with symptoms suggestive of active COVID-19 infection (e.g., fever, cough, dyspnea) and/or contact within the last 14 days with a suspected or confirmed COVID-19 patient.
* Positive pregnancy test, pregnant women, those currently breastfeeding, or those planning pregnancy during the study period.
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Laboratorios Silanes S.A. de C.V.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Isabel E Rucker-Joerg, MD
Role: PRINCIPAL_INVESTIGATOR
Clinical Research Institute S.C.
Ivonne A Torres-Quiroz, MD
Role: PRINCIPAL_INVESTIGATOR
Unidad de Medicina Especializada SMA
Adelfia Urenda-Quezada, MD
Role: PRINCIPAL_INVESTIGATOR
Servicios Avanzados de Investigación Médica Mediadvance, S.C.
Martha V Chavira-Flores, MD
Role: PRINCIPAL_INVESTIGATOR
Consultorio Médico "Dr. Rodrigo Suárez Otero"
Rodrigo Suarez-Otero, MD
Role: PRINCIPAL_INVESTIGATOR
IMACEN S.A. de C.V.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Laboratorio Silanes, S.A. de C.V.
Mexico City, , Mexico
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Ebrahimzadeh MH, Makhmalbaf H, Birjandinejad A, Keshtan FG, Hoseini HA, Mazloumi SM. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) in Persian Speaking Patients with Knee Osteoarthritis. Arch Bone Jt Surg. 2014 Mar;2(1):57-62. Epub 2014 Mar 15.
Puljak L, Marin A, Vrdoljak D, Markotic F, Utrobicic A, Tugwell P. Celecoxib for osteoarthritis. Cochrane Database Syst Rev. 2017 May 22;5(5):CD009865. doi: 10.1002/14651858.CD009865.pub2.
Krieckaert CL, van Tubergen A, Gehin JE, Hernandez-Breijo B, Le Meledo G, Balsa A, Bohm P, Cucnik S, Elkayam O, Goll GL, Hooijberg F, Jani M, Kiely PD, McCarthy N, Mulleman D, Navarro-Compan V, Payne K, Perry ME, Plasencia-Rodriguez C, Stones SR, Syversen SW, de Vries A, Ward KM, Wolbink G, Isaacs JD. EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2023 Jan;82(1):65-73. doi: 10.1136/annrheumdis-2022-222155. Epub 2022 May 12.
Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, Towheed T, Welch V, Wells G, Tugwell P; American College of Rheumatology. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012 Apr;64(4):465-74. doi: 10.1002/acr.21596.
Busse JW, Bartlett SJ, Dougados M, Johnston BC, Guyatt GH, Kirwan JR, Kwoh K, Maxwell LJ, Moore A, Singh JA, Stevens R, Strand V, Suarez-Almazor ME, Tugwell P, Wells GA. Optimal Strategies for Reporting Pain in Clinical Trials and Systematic Reviews: Recommendations from an OMERACT 12 Workshop. J Rheumatol. 2015 Oct;42(10):1962-1970. doi: 10.3899/jrheum.141440. Epub 2015 May 15.
Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, Callahan L, Copenhaver C, Dodge C, Felson D, Gellar K, Harvey WF, Hawker G, Herzig E, Kwoh CK, Nelson AE, Samuels J, Scanzello C, White D, Wise B, Altman RD, DiRenzo D, Fontanarosa J, Giradi G, Ishimori M, Misra D, Shah AA, Shmagel AK, Thoma LM, Turgunbaev M, Turner AS, Reston J. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol. 2020 Feb;72(2):220-233. doi: 10.1002/art.41142. Epub 2020 Jan 6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SIL-30221-III-23(1)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.